Jacobs Levy Equity Management’s Theriva Biologics TOVX Stock Holding History

Jacobs Levy Equity Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11	Closed	-$31K	–	1105
2018 Q1	$31K	Hold	11	–	–	﹤0.01%	985
2017 Q4	$49K	Hold	11	–	–	﹤0.01%	968
2017 Q3	$90K	Buy	+11	New	+$63.6K	﹤0.01%	920
2016 Q3	–	Sell	-3	Closed	-$44K	–	1131
2016 Q2	$44K	Buy	+3	New	+$56.5K	﹤0.01%	1126

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management's TOVX Position: Q2 2018 in Review

Jacobs Levy Equity Management sold out of Theriva Biologics (TOVX) in Q2 2018, closing a stake of 11 shares — an estimated $31K sold.

Jacobs Levy Equity Management first reported a position in TOVX in Q2 2016 and held it in 4 quarters. The position peaked at $90K in Q3 2017. 46 funds tracked by Wall St. Rank hold TOVX as of Q2 2018.

Jacobs Levy Equity Management reported no remaining Theriva Biologics position as of Q2 2018 after selling out during the quarter.
Jacobs Levy Equity Management sold 11 Theriva Biologics shares in Q2 2018, an estimated $31K.
Jacobs Levy Equity Management first reported a position in Theriva Biologics in Q2 2016 and held it in 4 quarters.
Jacobs Levy Equity Management's Theriva Biologics position peaked at $90K in Q3 2017.
46 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2018, filed 14 Aug 2018.